Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

• Long, Georgina V. Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia;
• Dummer, Reinhard University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland;
• Hamid, Omid The Angeles Clinic and Research Institute, Los Angeles, CA;
• Gajewski, Thomas University of Chicago Medical Center, Chicago, IL;
• Caglevic, Christian Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile;
• Dalle, Stéphane Hospices Civils De Lyon, Pierre-Bénite, France;
• Arance, Ana Hospital, Richmond, United Kingdom;
• Carlino, Matteo S. Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia;
• Grob, Jean-Jacques Dermatology department, CHRU, AP-HM Hôpital de la Timone , Marseille France, Marseille, France;
• Kim, Tae Min Seoul National University Hospital, Seoul, Korea, Republic of (South);
• Demidov, Lev V. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia;
• Robert, Caroline Gustave Roussy Institute, Paris, France;
• Larkin, James M. G. The Royal Marsden Hospital, London, United Kingdom;
• Anderson, James Merck & Co., Inc., Kenilworth, NJ;
• Maleski, Janet E. Incyte Corporation, Wilmington, DE;
• Jones, Mark M. Incyte Corporation, Wilmington, DE;
• Diede, Scott J. Merck & Co., Inc., Kenilworth, NJ;
• Mitchell, Tara C. Abramson Cancer Center, Philadelphia, PA;

Cancer Research

Oncology